Christian Bryant

Featured in: Favicon

mja.com.au Favicon

onlinelibrary.wiley.com

Articles

A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies

Jul 2, 2024 | onlinelibrary.wiley.com | Eric Li |Esther Jones |Christian Bryant |Tracy King

What is the new aspect of your work? This is the first study to report the efficacy and safety of PCAB (prednisone, cyclophosphamide, doxorubicin, carmustine), a single-day polychemotherapy regimen in relapsed and refractory multiple myeloma (RRMM) in the era of novel therapies. What is the central finding of your work?

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →